In a study published in Science Translational Medicine, a team of researchers led by Dr. Wang Yu from the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences developed PRINCE and Little Prince, dual small-molecule-controlled genome editing systems that allow CRISPR activity to be switched on by drug inducers and kept largely silent in their absence.